This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

H.C. Wainwright Remains a Buy on Emergent Biosolutions (EBS)

Tipranks - Tipranks - Thu Apr 30, 5:48AM CDT

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Emergent Biosolutions today and set a price target of $12.00.

Claim 55% Off TipRanks

Selvaraju covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Aclaris Therapeutics, and Emergent Biosolutions. According to TipRanks, Selvaraju has an average return of 22.4% and a 54.49% success rate on recommended stocks.

Emergent Biosolutions has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

See the top stocks recommended by analysts >>

Based on Emergent Biosolutions’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $148.7 million and a GAAP net loss of $54.6 million. In comparison, last year the company earned a revenue of $194.7 million and had a GAAP net loss of $31.3 million

Read More on EBS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).